SToMP-AD
Senolytic Therapy to Modulate Progression of Alzheimer’s Disease (SToMP-AD)
Purpose of this Study
The underlying processes driving chronic neurodegeneration in Alzheimer’s disease (AD) and related neurodegenerative disorders are largely unknown. Moreover, individuals with AD suffer from more age-associated health conditions than other older adults without AD. This research will use a combination of oral medications (dasatinib and quercetin) in an intermittent administration regimen for 12 weeks to identify whether the treatment will reach the spinal fluid or cross the blood-brain barrier and whether if it can affect the cellular life cycle and cellular inflammation that goes with aging.
You may qualify if:
- Age 65 and older
- A non-smoker
- Diagnosed with Alzheimer’s disease
- Must be accompanied by an authorized representative or family member
You may NOT qualify if:
- Have plans to travel over the study course of 4-5 months
- Have a currently active illness or other unstable chronic condition
Duration of the Study:
This is a 16 to 20-week study with up to 10 study visits.
Study Procedures:
- Medical history
- Physical examination/assessment
- Lab work
- MRI Testing
Study Location:
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
7703 Floyd Curl Drive
San Antonio, TX 78229
Compensation:
Up to $625 is offered for the completion of this study, depending on completed visits and procedures.
Principal Investigator:
Mitzi Gonzales, PhD
Nicolas Musi, MD
Contact Us
For more information or to volunteer in a study:
- Call (210) 567-8229
- If you prefer that we contact you, please fill out the form below.
